The short answer
KPV is supplied lyophilised and most stable dry, cold and dark. With no cysteine, methionine or asparagine, the common chemical degradation routes do not apply, leaving hydrolysis and, more practically, physical loss through adsorption to container surfaces.
Key facts
- Supplied as
- White lyophilised powder
- Disulfide risk
- None (no cysteine)
- Oxidation risk
- None (no methionine)
- Deamidation
- No asparagine
- Protease resistance
- Aided by proline
- Main practical loss
- Adsorption to surfaces
Chemically among the simplest
Three residues, none of them carrying a reactive functional group beyond lysine's amine. No thiol to oxidise or scramble, no thioether, no amide side chain prone to deamidation. Two peptide bonds is the entire hydrolysable content of the molecule. As research peptides go, KPV is close to inert.
Why adsorption matters more here
A small, positively charged molecule binds readily to glass and plastic surfaces. At the low absolute quantities a 342 Da compound is often used in, the fraction lost to a vial wall and pipette tips can be a substantial share of the material. It is also a silent loss, since what remains is chemically intact. Low-binding consumables and minimal transfers are the practical response.
Research material referenced
KPV 10mg, third-party HPLC tested
The proline contribution
Proline-adjacent peptide bonds resist most peptidases, and in a three-residue peptide one proline covers a large proportion of the available bonds. That gives real enzymatic stability, though it does nothing against simple chemical hydrolysis in solution over time.
Reconstitution
Introduce diluent gently down the vial wall and swirl rather than shake. KPV is small and highly soluble, so it dissolves readily and vigorous agitation is never needed. Foaming indicates an air-liquid interface has been created, which is where peptides denature. That is less of a concern for a molecule this small and unstructured than for a lipidated 39-mer, but still avoidable.
After reconstitution
Aliquot into single-use volumes rather than freeze-thawing. The chemical robustness that protects KPV against oxidation does nothing about the physical stresses of repeated cycling, and for a compound this prone to surface adsorption, minimising handling steps is the more important discipline.
Frequently asked questions
Does KPV need a reducing agent?
No. There is no cysteine in the sequence.
Why might I recover less than expected?
Adsorption to glass and plastic. A small, positively charged molecule binds surfaces, and at low quantities that loss is significant.
Is KPV unusually stable?
Chemically, yes: no cysteine, methionine or asparagine, and only two hydrolysable bonds. Physical loss is the more likely problem.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More KPV articles
- Fragment Logic: KPV Against Its ParentIsolating three residues from a thirteen-residue hormone separates one function from another. What that buys, and what it cannot guarantee.
- What the Colitis Models ReportedKannengiesser 2008 reported anti-inflammatory potential in murine colitis. What a disease model establishes, and the gap before any clinical claim.
- KPV in the Published LiteratureAbout 34 indexed records, mostly murine and cell culture. How to search a compound whose abbreviation collides with an unrelated chemical.
- KPV Regulatory StatusNo marketing authorisation anywhere. Why an anti-inflammatory literature makes the claims boundary particularly easy to cross.
- The Transporter That Explains the TripeptideKPV is a substrate for PepT1, the intestinal di- and tripeptide transporter. That single fact organises almost everything published about this molecule.